Table 2.
Comparison of stroke treatment details during the study period between 2019 and 2020.
| Feb-July 2019 | Feb-July 2020 | p value | q value | |
|---|---|---|---|---|
| Door to CT time | 30(30) | 30(30) | 0.47 | |
| N = 1073 | N = 1136 | |||
| Thrombolysis | 182(17.93%) | 230 (21.84%) | 0.03 | 0.06 |
| N = 1015 | N = 1053 | |||
| *Onset to needle time | 190 (77.5) | 185.5(88.5) | 0.74 | |
| N = 168 | N = 216 | |||
| *Door to needle | 47(40) | 57(35) | 0.01 | 0.02 |
| N = 167 | N = 214 | |||
| *CT to needle | 24(25) | 30(26) | 0.005 | 0.001 |
| N = 166 | N = 214 | |||
| EVT | 74 (63.25%) | 43 (36.75%) | 0.00007 | 0.0003 |
| N = 471 | N = 542 | |||
| *CT to puncture time | 64(41) | 59(61) | 0.46 | |
| N = 67 | N = 39 | |||
| *Puncture to recanalization time | 56 (46) | 45(36) | 0.35 | |
| N = 52 | N = 35 | |||
| Recanalization | 57 (82.6%) | 38 (92.6%) | 0.13 | |
| N = 69 | N = 41 | |||
| *Total procedure time | 90 (45) | 75 (68) | 0.21 | |
| N = 54 | N = 34 | |||
| Aspirin | 833(86.77%) | 806(86.75%) | 0.99 | |
| N = 960 | N = 929 | |||
| Clopidogrel | 468(54.86%) | 515(55.97%) | 0.23 | |
| N = 853 | N = 920 | |||
| Statin | 885 (91.52%) | 854(86.18%) | 0.0001 | |
| N = 967 | N = 991 | |||
| OAC | 109 (22.19%) | 64 (21.47%) | 0.81 | |
| N = 491 | N = 298 | |||
| Surgical intervention | 100 (18.38%) | 67 (17.31%) | 0.67 | |
| N = 544 | N = 387 | |||
| Type of surgical intervention | ||||
| DCH | 57 (58.1%) | 32(49.23%) | ||
| Hematoma evacuation | 13(13.26%) | 11(16.92%) | ||
| EVD | 10 (10.2%) | 6 (9.23%) | ||
| DCH + HE | 11(11.22%) | 8(12.3%) | ||
| Endarterectomy | 0 | 4 (6.15%) | ||
| Stenting | 7 (7.14%) | 4 (6.15%) | ||
| N = 98 | N = 65 |
Data is in n% or mean+/SD or median (IQR). N denotes available data; * duration in minutes; EVT: Endovascular Therapy; OAC: Oral Anticoagulant; DCH: Decompressive Hemicraniectomy; EVD: External Ventricular Drain; HE: Hematoma Evacuation.